Results of a phase II clinical trial conducted at MD Anderson Cancer Center revealed combination targeted therapy, consisting of rituximab, lenalidomide, and ibrutinib, had an 84.6% overall response rate and 38.5% complete response rate when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large B-cell lymphoma.
Small dreams have no power to move hearts, and in a new six-year strategic plan, St. Jude Children’s Research Hospital is thinking very big. What would it take to drastically increase cure rates for childhood cancer worldwide?
